Abstract
Polyoxometalate (POM) has promising antiviral activities. It shows broad-spectrum inhibiting ability, high efficiency, and low toxicity. Experimental assays show that titanium containing polyoxotungstates have anti-influenza-virus activity. In this paper, the binding mechanisms of five isomers of di-Ti-substituted polyoxotungstate, [α-1,2-PTi2W10O40]7− (α-1,2), [α-1,6-PTi2W10O40]7− (α-1,6), [α-1,5-PTi2W10O40]7− (α-1,5), [α-1,4-PTi2W10O40]7− (α-1,4) and [α-1,11-PTi2W10O40]7− (α-1,11), to five subtypes of influenza virus A neuraminidase (FluV-A NA) were investigated in the context of aqueous solution by using molecular docking and molecular dynamics studies. The results show that the isomer α-1,2 is superior to other isomers as a potential inhibitor to neuraminidase. The positively charged arginine residues around the active site of NA could be induced by negatively charged POM to adapt themselves and could form salt bridge interactions and hydrogen bond interactions with POM. The binding free energies of POM/NA complexes range from −5.36 to −8.31 kcal mol−1. The electrostatic interactions are found to be the driving force during the binding process of POM to NA. The conformational analysis shows that POM tends to bind primarily with N1 and N8 at the edge of the active pocket, which causes the conformational change of the pincers structure comprising residue 347 and loop 150. Whereas, the active pockets of N2, N9 and N4 are found to be more spacious, which allows POM to enter into the active pockets directly and anchor there firmly. This study shows that negatively charged ligand as POM could induce the reorganization of the active site of NA and highlights POM as a promising inhibitor to NA despite the ever increasing mutants of NA.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wingard J R. Facing the next pandemic: Ready or not. Biol Blood Marrow Transplant, 2007, 13: 107–109
Trampuz A, Prabhu R M, Smith T F, et al. Avian influenza: A new pandemic threat? Mayo Clin Proc, 2004, 79: 523–530
Palese P. Influenza: Old and new threats. Nat Med, 2004, 10: S82–S87
Le Q M, Kiso M, Someya K, et al. Avian flu: Isolation of drugresistant H5N1 virus. Nature, 2005, 437: 1108–1108
Ungchusak K, Auewarakul P, Dowell S F, et al. Probable personto-person transmission of avian influenza A (H5N1). New Engl J Med, 2005, 352: 333–340
Guan Y, Poon L L M, Cheung C Y, et al. H5N1 influenza: A protean pandemic threat. Proc Natl Acad Sci USA, 2004, 101: 8156–8161
Chen J M, Sun Y X, Liu S, et al. Origin and future distribution of the new A (H1N1) influenza virus emerging in North America in 2009. Chinese Sci Bull, 2009, 54: 2174–2178
Smee D F, Huffman J H, Morrison A C, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Ch, 2001, 45: 743–748
Crusat M, de Jong M D. Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir Ther, 2007, 12: 593–602
De Clereq E, Neyts J. Avian influenza A (H5N1) infection: Targets and strategies for chemotherapeutic intervention. Trends Pharmacol Sci, 2007, 28: 280–285
Hurt A C, Ho H T, Barr I. Resistance to anti-influenza drugs: Adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther, 2006, 4: 795–805
Kiso M, Mitamura K, Sakai T Y, et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet, 2004, 364: 759–765
Regoes R R, Bonhoeffer S. Emergence of drug-resistant influenza virus: Population dynamic considerations. Science, 2006, 312: 389–391
Bantia S, Arnold C S, Parker C D, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antivir Res, 2006, 69: 39–45
Baum E Z, Wagaman P C, Ly L, et al. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antivir Res, 2003, 59: 13–22
Yun N E, Linde N S, Zacks M A, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology, 2008, 374: 198–209
Barnard D L, Hill C L, Gage T, et al. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antivir Res, 1997, 34: 27–37
Shigeta S, Mori S, Watanabe J, et al. Anti-influenzavirus-activities of polyoxometalates. Antivir Res, 1995, 26: A298
Rhule J T, Hill C L, Judd D A. Polyoxometalates in medicine. Chem Rev, 1998, 98: 327–357
Cindric M, Veksli Z, Kamenar B. Polyoxomolybdates and polyoxomolybdovanadates-from structure to functions: Recent Results. Croat Chem Acta, 2009, 82: 345–362
Yamase T. Anti-tumor, -viral, and -bacterial activities of polyoxometalates for realizing an inorganic drug. J Mater Chem, 2005, 15: 4773–4782
Hill C L, Weeks M S, Schinazi R F. Anti-HIV-1 activity, toxicity, and stability studies of representative structural families of polyoxometalates. J Med Chem, 1990, 33: 2767–2772
Witvrouw M, Weigold H, Pannecouque C, et al. Potent anti-HIV (type 1 and type 2) activity of polyoxometalates: structure-activity relationship and mechanism of action. J Med Chem, 2000, 43: 778–783
Liu J, Mei W J, Xu A W, et al. Synthesis, characterization and antiviral activity against influenza virus of a series of novel manganese-substituted rare earth borotungstates heteropolyoxometalates. Antivir Res, 2004, 62: 65–71
Shigeta S, Mori S, Yamase T, et al. Anti-RNA virus activity of polyoxometalates. Biomed Pharmacother, 2006, 60: 211–219
Rozenbaum W, Dormont D, Spire B, et al. Antimoniotungstate (HPA 23) treatment of three patients with aids and one with prodrome. Lancet, 1985, 325: 450–451
Moskovitz B L. Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome. Antimicrob Agents Ch, 1988, 32: 1300–1303
Take Y, Tokutake Y, Inouye Y, et al. Inhibition of proliferation of human immunodeficiency virus type 1 by novel heteropolyoxotungstates in vitro. Antivir Res, 1991, 15: 113–124
Fukuma M, Seto Y, Yamase T. In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes-simplex virus. Antivir Res, 1991, 16: 327–339
Ikeda S, Nishiya S, Yamamoto A, et al. Activity of the Keggin polyoxotungstate PM-19 against herpes-simplex virus type-2 infection in immunosuppressed mice-role of peritoneal macrophage activation. J Med Virol, 1993, 41: 191–195
Shigeta S, Mori S, Watanabe J, et al. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob Agents Ch, 1997, 41: 1423–1427
Zhang G, Keita B, Craescu C T, et al. Molecular interactions between Wells-Dawson type polyoxometalates and human serum albumin. Biomacromolecules, 2008, 9: 812–817
Zhang G, Keita B, Craescu C T, et al. Polyoxometalate binding to human serum albumin: A thermodynamic and spectroscopic approach. J Phys Chem B, 2007, 111: 11253–11259
Zheng L, Ma Y, Zhang G J, et al. A multitechnique study of europium decatungstate and human serum albumin molecular interaction. Phys Chem Chem Phys, 2010, 12: 1299–1304
Zheng L, Ma Y, Zhang G J, et al. Molecular Interaction between a Gadolinium-Polyoxometalate and Human Serum Albumin, Eur J Inorg Chem, 2009, 34: 5189–5193
Sarafianos S G, Kortz U, Pope M T, et al. Mechanism of polyoxometalate-mediated inactivation of DNA polymerases: an analysis with HIV-1 reverse transcriptase indicates specificity for the DNA-binding cleft. Biochem J, 1996, 319: 619–626
Judd D A, Nettles J H, Nevins N. Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. J Am Chem Soc, 2001, 123: 886–897
Russell R J, Haire L F, Stevens D J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature, 2006, 443: 45–49
Varghese J N, Epa V C, Colman P M. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci, 1995, 4: 1081–1087
Varghese J N, McKimm-Breschkin J L, Caldwell J B, et al. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins, 1992, 14: 327–332
Comba P. The relation between ligand structures, coordination stereochemistry, and electronic and thermodynamic properties. Coordin Chem Rev, 1993, 123: 1–48
Cundari T R, Moody E W, Sommerer S O. Computer-aided design of metallopharmaceuticals: A molecular mechanics force field for gadolinium complexes. Inorg Chem, 1995, 34: 5989–5999
Cundari T R, Sisterhen L L, Stylianopoulos C. Molecular modeling of vanadium peroxides. Inorg Chem, 1997, 36: 4029–4034
Viloya S A, Christine M K, Clark R L. SHAPES empirical force field: New treatment of angular potentials and its application to square-planar transition-metal complexes. J Am Chem Soc, 1991, 113: 1–12
Menke C, Diemann E, Müller A. Polyoxovanadate clusters and cages: Force-field parameterization. J Mol Struct, 1997, 436–437: 35–47
Guan W, Yan L K, Su Z M, et al. Electronic properties and stability of dititaniumIV substituted α-Keggin polyoxotungstate with heteroatom phosphorus by DFT. Inorg Chem, 2005, 44: 100–107
Alberts I L, Todorov N P, Källbku P, et al. Ligand docking and design in a flexible receptor site. QSAR Combin Sci, 2005, 24: 503–507
Hu D H, Shao C, Guan W, et al. Studies on the interactions of Ti-containing polyoxometalates (POMs) with SARS-CoV 3CLpro by molecular modeling. J Inorg Biochem, 2007, 101: 89–94
Ajloo D, Behnam H, Saboury A A, et al. Thermodynamic and structural studies on the human serum albumin in the presence of a polyoxometalate. Bull Korean Chem Soc, 2007, 28: 730–736
Zhang G, Keita B, Brochon J C. Molecular interaction and energy transfer between human serum albumin and polyoxometalates. J Phys Chem B, 2007, 111: 1809–1814
Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Mol Biol, 1996, 3: 927–933
Cao Y, Musah R A, Wilcox S K, et al. Protein conformer selection by ligand binding observed with crystallography. Protein Sci, 1998, 7: 72–78
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
About this article
Cite this article
Wang, J., Hu, D. & Su, Z. Molecular simulation study of the binding mechanism of [α-PTi2W10O40]7− for its promising broad-spectrum inhibitory activity to FluV-A neuraminidase. Chin. Sci. Bull. 55, 2497–2504 (2010). https://doi.org/10.1007/s11434-010-3271-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-010-3271-8